The ovarian cancer drug market
This article discusses the impact of the recent approvals of poly ADP ribose polymerase (PARP) inhibitors on the market for ovarian cancer drugs, as well as potential future treatments such as immunotherapies.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Jennifer Bamford Rachel M. Webster Tags: News and Analysis Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Immunotherapy | Ovarian Cancer | Ovaries